Should I Buy HIMS? HIMS 2026 Analysis

Should You Buy Hims & Hers Health Inc (HIMS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

23.020

1 Day change

-1.96%

52 Week Range

72.980

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient trader: the primary trend is still bearish (price below key moving averages, MACD worsening), so catching the dip has unfavorable odds.
Oversold conditions (RSI_6 ~18) can produce a sharp bounce, but without an Intellectia buy signal this looks more like a tactical dead-cat bounce setup than a high-conviction entry.
Near-term headline risk remains elevated into earnings (2026-02-23) and GLP-1 competitive pressure could keep sentiment heavy.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend: Bearish. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), indicating sustained downside momentum.
Momentum: MACD histogram -0.391 and negatively expanding → selling pressure is increasing, not fading yet.
RSI: RSI_6 at ~18.1 → deeply oversold; probability of a short-term relief bounce is rising, but oversold can persist in downtrends.
Key levels: Price (24.52) is below S1 (25.06) and above S2 (23.40). If S2 breaks, downside can accelerate; a bounce would first need to reclaim ~25.06, then pivot ~27.73 to improve structure.
Pattern-based forward stats (similar candlesticks): skew slightly negative over the next week (model suggests higher chance of further weakness).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment skew: Call-leaning. OI put/call 0.71 and volume put/call 0.36 suggest traders are positioning more bullish/less hedged than bearish.
Volatility: Implied vol (30d) ~101.9% vs historical vol ~52.9% → options are pricing large moves (expensive premiums), consistent with event risk (earnings + business-model headlines).
Activity: Today’s option volume is ~62.8% of 30-day average → not a “capitulation” volume day; positioning looks constructive but not a decisive risk-on surge.

Technical Summary

Sell

Buy

Positive Catalysts

- Product expansion catalyst: Launch of Galleri multi-cancer early detection test broadens the lab/diagnostics offering and can support higher LTV and subscription stickiness.
- Flow/support: Hedge funds are buying (reported +211.82% QoQ increase in buying amount), providing a potentially supportive demand tailwind.
- Contrarian setup: Deeply oversold RSI increases chances of a sharp rebound if any positive catalyst hits (good guidance/earnings beat or improved GLP-1 narrative).

Neutral/Negative Catalysts

earnings on 2026-02-23 could re-rate the stock quickly; with high IV, the market is explicitly bracing for a large move.

Financial Performance

Latest quarter provided: 2025/Q3.
Growth: Revenue rose to ~$599.0M, up ~49.2% YoY (strong top-line momentum).
Profitability: Net income fell to ~$15.8M (-79.1% YoY) and EPS fell to $0.06 (-81.3% YoY) → growth is being bought with heavier costs/investment.
Margins: Gross margin slipped to ~73.8% (-6.8% YoY), indicating mix/pricing/cost pressures versus last year.
Takeaway: Excellent revenue growth, but the quarter shows clear margin compression and earnings deterioration—supporting the “investment year / expectations too high” bear argument.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Price targets have been cut and skepticism has increased around 2026 profitability and GLP-1 sustainability.
Bulls: Barclays initiated Overweight with $48 (thesis: compounding concerns better understood; additional growth drivers improve durability). BTIG kept Buy but cut PT to $60 from $85 (still constructive, but dialing back expectations).
Bears: BofA Underperform with $29 (expects downside to 2026 revenue/EBITDA margins; expects negative revisions). Citi Sell with $30 (expects Wegovy availability to pressure HIMS GLP-1 business in 2026).
Wall Street pros/cons view: Pros focus on diversified growth drivers and product expansion; cons focus on GLP-1 headwinds and a profitability/margin outlook that may be overestimated by consensus.

12 Analyst Rating

Wall Street analysts forecast HIMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIMS is 42.88 USD with a low forecast of 29 USD and a high forecast of 85 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

7 Hold

3 Sell

Hold

Current: 23.480

Low

Averages

42.88

High

Current: 23.480

Low

Averages

42.88

High

BTIG

Buy

downgrade

$85 -> $60

AI Analysis

2026-02-02

Reason

BTIG

Price Target

$85 -> $60

AI Analysis

2026-02-02

downgrade

Buy

Reason

BTIG lowered the firm's price target on Hims & Hers to $60 from $85 and keeps a Buy rating on the shares as part of a broader research note previewing Q4 for Healthcare IT and Digital Health names.

BofA

Underperform

downgrade

$32 -> $29

2026-01-08

Reason

BofA

Price Target

$32 -> $29

2026-01-08

downgrade

Underperform

Reason

BofA lowered the firm's price target on Hims & Hers to $29 from $32 and keeps an Underperform rating on the shares. The firm says 2026 consensus estimates for Hims' sales and EBITDA margins are too high. 2026 is a "big investment year" for Hims & Hers and current Street expectations for EBITDA margin expansion "seem overly optimistic," the analyst tells investors in a research note. BofA sees downside risk to 2026 consensus revenue and EBITDA margins and expects negative earnings revisions to take place over the next few months.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HIMS

Unlock Now

HIMS Should I Buy

HIMS Should I Buy

Should You Buy Hims & Hers Health Inc (HIMS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch